Not to forget for mondyinvest—Clarity’s ligand alone is also very valuable, & took many years to develop through the past decade.
Also in no way is CU6 a single diagnostic or treatment & reliant on one trial or outcome . True real value already well and truly held now .
(Opthea knocked back multiple partnership offers , which could have lead to a better trial design/ endpoints ,as understand it. I never followed the company or story at all, did not get into it. The funding terms however I find to have been completely shocking. To me the former CEO and board should not have been applauded for their deal wrt funding & raising money for the company- the absolute risk was a travesty, Was completely unacceptable risk. )
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)